Member Info for Wiggly

The pressure is starting to build and it wont be long until we surpass our all time high.

I will say very deliberate! AS has dropped a massive hint within the RNS that ABCAM will also drive the global distribution of the Affimer Spike reagents, perhaps on an exclusive basis (just a hunch).

Deliberate or not?

Spot the difference;

1.

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group's recently developed SARS-CoV-2 research ELISA Affimer® reagents.

2.

Dr Alastair Smith, Chief Executive of Avacta Group commented:

"We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer® reagents through ABCAM's dedicated global commercialisation infrastructure.

If you have held here for many months, the one thing you should now have learned is to expect nothing but disappointment tomorrow.

I have lived this share on repeat - very high expectation followed by disappointment.

With that said, I do expect we have finally reached the end of a very long and winding path. tomorrow should be fun.

Matt,

9:17 and 72 posts............ relax folks.

Says the man with 563 posts in the last 30 days LOL

Wyn,

The choice is really simple.

- Twice weekly testing for all, for years, to ensure CV never rises to a lock down level again, or;
- Twice weekly testing for 2 months, take the foot off the gas and risk CV rising to a level that requires lock down in the future?

The cost of twice weekly testing vs cost of a lock down is very clear to the Gov.

The government said that for every 1,000 lateral flow tests carried out, there was less than one false positive result, and the rapid tests were particularly useful at detecting high levels of virus.

If they did say that then I believe they can only be referring to AVCT. This is where the Affimers come into their own, and is what SIR AL has been banging on about for months. With the data we have, no other LFT could deliver such specificity.

This volume is far higher than our forecasts but then AS has said multiple times that the volume stated could be increased substantially with investment - he has also mentioned a need to supply 100m+ per month. I suspect the investment referenced is investment from the UK Gov, which he has not been able to disclose publicly for obvious reasons.

- Worst case, AVCT will play its part towards the supply of the 100m, supplying what it can from its capacity with BBI/Abington/Medusa (is this the dark horse?).

Best case, AVCT will be preferred test and will supply a significant chunk of the volume, via capacity with GAD/Mologic, ODX, BBI, Abington, Medusa and others yet to be named. (The link between all and AVCT suggest this case is probable)

Best case follow on, AVCT will supply the reagent globally (US + Europe) and the $$$ incoming will make this story legendary on AIM!

It is too late to ramp or deramp now as all is going to be revealed before you can trade, so for what it is worth, there have been far too many coincidences in this story for AVCT not to be central. I am therefore of the opinion that the following week is going to be unbelievable for AVCT holders.

Would love for news to be released today so we have something to discuss this weekend other than will we/wont we receive an RNS on Tuesday or was it/was it not a sell?

Please AS! Deliver it today!

Another monster from yesterday just appeared.

31-Mar-21 16:20:25 217.38115 434,090 Sell* 242.00 245.00 943.63k

It takes time for a leak to be known widely. Big buys today (£230k +) backed by multiple 10k purchases could suggest news is beginning to leak.

Seems to be in a hurry.

AJ242 - much higher than 6% is coming.

Seriously - looks like a real leak!! MM will take everything I have at 235 offer!

.

Some months ago Danaher/Cytiva were rumoured to be bringing a Rapid Antigen LFT to market. Has there been any news on this?

AS once described Cytiva as a great partner with 'real scale'. I believe Cytiva were also investing massively to upgrade production capabilities?

It would be wrong to assume that Cytiva, who have had direct insight into the performance of the Affimers (we know 96.7/100 based on publicly announced clinical validation) would not be very interested in the use of the Affimers within their branded LFT.

Klaus Hochleitner, Global Lead, Technology Product Specialist at Cytiva, once commented:

"The Affimer reagents have worked well in lateral flow test strips and we are VERY encouraged by the initial data"

The FDA news is certainly a big one and I think it could be the catalyst for multiple (or perhaps just an exclusive!) deal with a US giant.

Watch this space!

The USP of an Affimer LFT cannot be understated though;

- ease of use (AN sample method)
- ability to rapidly reformulate the Affimer package to ensure it picks of the Variant of the day (can the others adjust the reagent as quickly as AVCT)?
- Very high Specificity (likely 100%)
- Sensitivity also likely to be very high (TBC, I am hopeful we see a surprise upwards..)
- LFT designed with scalability in mind

Or inaction, speaks volumes.

Good point from Radia.

- The probability that DHSC have real time line of sight to the AVCT CV performance is very high.
- The need to get moving with the Sovereign test is a matter of urgency (hours + days count in this situation)
- If the AVCT test was performing badly (vs initial CV) I think the Gov would have moved already to progress the Sovereign test with the preferred reagent.

While no news has been portrayed as negative, if you consider the above, I think this is beginning to look extremely positive!

yes, NT and bid very strong...

Come on AS, deliver the big one!

Looks ready to blow. A 130/2pm RNS would make my day!